[Drug therapy in supraventricular arrhythmia].
In view of their potentially dangerous proarrhythmic effects, antiarrhythmic drugs should only be prescribed for patients with poorly tolerated symptomatic supraventricular arrhythmias. The choice of a suitable preparation depends not only on the type of arrhythmia, but also on the underlying heart disease and left-ventricular function. Digoxin, verapamil, sotalol and quinidine remain first-line drugs, while in view of recent trials the type-1c antiarrhythmics (flecainide) should only be given in cases resistant to other agents. Amiodarone is also an important and efficacious "reserve" antiarrhythmic, which has to be utilized at low doses to avoid its well-known side effects.
Follath
F
F
Departement für Innere Medizin, Universitätsspital Zürich.
Candinas
R
R
Meyer
B
B
D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000145:classification / Q000627:therapeutic use*; D004077:Digoxin / Q000627:therapeutic use; D005424:Flecainide / Q000627:therapeutic use; D006801:Humans; D011802:Quinidine / Q000627:therapeutic use; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D004077:Digoxin; D011802:Quinidine; D005424:Flecainide; D000638:Amiodarone
Medikamentöse Therapie bei supraventrikulären Arrhythmien.